Featured Research

from universities, journals, and other organizations

Fruit Fly Protein Acts As Decoy To Capture Tumor Growth Factors

Date:
June 2, 2008
Source:
University of Pennsylvania School of Medicine
Summary:
Researchers at the University of Pennsylvania School of Medicine have shown how Argos, a fruit fly protein, acts as a "decoy" receptor, binding growth factors that promote the progression of cancer. Knowing how Argos neutralizes tumor growth may lead to new drug designs for inhibiting cancer.

How Argos, a fruit fly protein, acts as a "decoy" receptor, binding and neutralizing growth factor molecules (green) that promote the progression of cancer.
Credit: Mark Lemmon, PhD, University of Pennsylvania School of Medicine

Researchers at the University of Pennsylvania School of Medicine have shown how Argos, a fruit fly protein, acts as a 'decoy' receptor, binding growth factors that promote the progression of cancer. Knowing how Argos neutralizes tumor growth may lead to new drug designs for inhibiting cancer. The study appeared online in Nature in advance of print publication.

Many types of tumors grow because of over-expression of a protein known as the epidermal growth factor receptor (EGFR) or a peptide hormone called epidermal growth factor (EGF) that binds and activates EGFR. Argos mimics EGFR by binding to EGF. But, unlike EGFR, Argos does not signal cells to grow.

In theory, surmise the researchers, a drug designed to resemble Argos could bind cancer growth factors and prevent them from signaling cancer cell growth. The investigators previously found that Argos works this way in the fruit fly, binding and neutralizing the fly version of EGF called Spitz. Inhibition of Spitz in this way is crucial for proper development of the fly eye.

"There are several 'designer' cancer drugs that fight tumors driven by EGFR-like receptors, such as Herceptin, Erbitux and Tarceva," says lead author Mark A. Lemmon, PhD, Professor of Biochemistry and Biophysics. "Whereas these drugs all attack the receptor itself, an Argos-like drug would instead neutralize the cancer growth factor by mimicking a silent receptor. This is a change in paradigm for tumor-growth inhibition in this class of cancers."

Approaches using molecules that neutralize growth factors have proven themselves in other cases. The Avastin antibody works well to block the molecule that activates the vascular endothelial growth factor receptor and several drugs can block tumor necrosis factor-α in arthritis, including Remicade, Humira and Enbrel. An Argos-like drug would work the same way in EGFR signaling, suggests Lemmon.

In the current study, Lemmon and colleagues have worked out the details of the three-dimensional structure of Argos when it binds to Spitz. "We were surprised to find that Argos has three very similar domains that capture Spitz by surrounding it like a C-clamp," explains Lemmon. Although Argos binding to Spitz mimics the characteristic binding of EGFR to EGF, Argos and EGFR do not share the same amino acid sequence or structural similarities.

The structure of Argos was studied by X-ray crystallography, a technique that shows where each atom of the protein is located. Computer analysis is then used to put together all the data into a three-dimensional projection of the growth factor and its binding molecule.

The next step is to identify a human protein that is similar in structure to Argos. Intriguingly, Argos shares structural similarities with the human receptors for transforming growth factor β and urokinase plasminogen activator. "There are quite a few other human proteins with similar predicted structures whose function is not yet known," says Lemmon. "We think that one of these might be a functional analogue of Argos, and we could exploit that as a drug."

Daryl E. Klein, Steven E. Stayrook, Fumin Shi, and Kartik Narayan, all of Penn, are co-authors on the study. This work was supported by grants from the National Cancer Institute and the U. S. Army Breast Cancer Research Program.


Story Source:

The above story is based on materials provided by University of Pennsylvania School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Daryl E. Klein, Steven E. Stayrook, Fumin Shi, Kartik Narayan & Mark A. Lemmon. Structural basis for EGFR ligand sequestration by Argos. Nature, Published online 25 May 2008 DOI: 10.1038/nature06978

Cite This Page:

University of Pennsylvania School of Medicine. "Fruit Fly Protein Acts As Decoy To Capture Tumor Growth Factors." ScienceDaily. ScienceDaily, 2 June 2008. <www.sciencedaily.com/releases/2008/05/080528155632.htm>.
University of Pennsylvania School of Medicine. (2008, June 2). Fruit Fly Protein Acts As Decoy To Capture Tumor Growth Factors. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/05/080528155632.htm
University of Pennsylvania School of Medicine. "Fruit Fly Protein Acts As Decoy To Capture Tumor Growth Factors." ScienceDaily. www.sciencedaily.com/releases/2008/05/080528155632.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins